Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Verigraft AB currently manages a company patent portfolio within the Biotechnology and Pharmaceuticals technology area. The portfolio shows 1 pending office action, indicating a focused or early-stage prosecution phase. This single action is distributed across 1 distinct examiner and 1 distinct art unit, suggesting a highly concentrated examination environment for the firm's intellectual property.
The busiest examiner for this portfolio is LAZARO, DOMINIC, who is currently handling 1 pending office action. Because the busiest examiner pending count is 1, the workload is entirely centered on this individual. For a practitioner, this means that the outcome of the current prosecution depends on the specific tendencies and requirements of this single examiner within the identified art unit.
The presence of 1 distinct art unit and 1 distinct examiner implies that the portfolio has not yet branched into diverse technical sub-specialties at the patent office. Prosecution strategy should remain focused on the specific standards of this art unit. Maintaining a clear line of communication with the assigned examiner is the primary task for managing the current 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAZARO, DOMINIC | 1 | 63.7% | +31.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18610699 | NERVE GRAFTS FOR PERIPHERAL NERVE REGENERATION | LAZARO, DOMINIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18610699 | NERVE GRAFTS FOR PERIPHERAL NERVE REGENERATION | LAZARO, DOMINIC | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18610699 | NERVE GRAFTS FOR PERIPHERAL NERVE REGENERATION | LAZARO, DOMINIC | 1611 | §102§103 | Final Rejection | — | Pending | Mar 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVerigraft AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dominic Lazaro has the most, with 1 of Verigraft AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
